LICENSE AND COLLABORATION AGREEMENT BETWEEN ORIC PHARMACEUTICALS, INC. AND VORONOI INC.License and Collaboration Agreement • May 9th, 2022 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AND COLLABORATION AGREEMENT (“Agreement”) dated as of 19th day of October, 2020 (“Effective Date”), is entered into between Voronoi Inc., a limited corporation duly established under the Republic of Korea’s commercial code having offices at S 18th F, Songdogwahak-ro 32[IT Center], Yeonsu-gu, Incheon, Korea (“Voronoi”) and ORIC Pharmaceuticals, Inc., a Delaware corporation having business offices at 240 East Grand Ave, 2nd Floor, South San Francisco, CA, 94080 (“ORIC”).
LICENSE AGREEMENTLicense Agreement • May 9th, 2022 • Oric Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (this “Agreement”), entered into as of August 3, 2020 (the “Effective Date”), is entered into by and between Mirati Therapeutics, Inc., a Delaware corporation having business offices at 9393 Towne Centre Drive, Suite 200, San Diego, California 92121 (“Mirati”), and ORIC Pharmaceuticals, Inc., a Delaware corporation having business offices at 240 East Grand Ave, 2nd Floor, South San Francisco, CA, 94080 (“ORIC”).
